M

Mogrify

76 employees

Mogrify® will transform the lives of patients with degenerative diseases through a novel class of in vivo reprogramming therapies.

Basic info

Industry

biotechnology

Sectors

Biotechnology
Life Science
Transcriptomics
Cell therapy
Stem cells
Direct cellular conversion
Health Care
Big Data
Bioinformatics
Machine learning
Therapeutics
Transmogrification
Drug discovery
Transdifferentiation
Big data
Regenerative medicine
Direct cell reprograming

Date founded

2019

Funding rounds raised

Total raised

$17M

from 11 investors over 11 rounds

M

Mogrify raised $10M on October 2, 2023

Investors: Ahren Innovation Capital, Parkwalk Advisors and Astellas Venture Capital L.L.C.

M

Mogrify raised $17M on May 4, 2021

Investors: Astellas Venture Capital L.L.C., Parkwalk Advisors and 24Haymarket

M

Mogrify raised $16M on October 14, 2019

Investors: 24Haymarket, Ahren Innovation Capital and Parkwalk Advisors

M

Mogrify raised $3.7M on February 20, 2019

Investors: 24Haymarket and Ahren Innovation Capital

FAQ